ACET Market Analysis
Wall Street coverage
third-party contextWall Street coverage
$33.17median target· current $9.01 (+268.1%)6 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
50 articles · sorted by datePage 1 of 3 · 50 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeP/E ratio—
EPS (TTM)$-9.020.0% YoY
Profit margin0.0%HEALTHCARE
Market cap$84.7MMicro cap
Valuation
- Forward P/E
- —
- PEG ratio
- 0.82
- P/B
- 0.66
- P/S (TTM)
- 9.72
- EV/EBITDA
- -1.21
Profitability & growth
- ROE (TTM)
- -78.1%
- Operating margin
- 0.0%
- Revenue growth YoY
- -100.0%
- Dividend yield
- —
- Beta
- 1.59
Last earnings
Aug 5, 2026 · Estimate $-2.43 · Reported $-1.99
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Adicet Bio Inc
Company profileAdicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company is headquartered in Boston, Massachusetts.
Classification
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 131 DARTMOUTH STREET, BOSTON, MA
- Fiscal year end
- December
- Latest quarter
- Jun 30, 2026
Market cap$84.7M
Shares outstanding$9.4M
52W high$17.44
52W low$6.01
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent